Stock listing

Frankfurt:B6E Swedish Orphan Biovitrum AB Aktie

German listing (Frankfurt) of Swedish Orphan Biovitrum AB · home listing Stockholm:SOBI

Follow Swedish Orphan Biovitrum AB into a list and get an email when it puts out news.

Share price · FWB:B6E

€44.48 EUR +2.78 (+6.7%)

Close on Oct 30, 2026

Day range
€44.48 – €44.48 EUROct 30, 2026
Market cap
€15.48B EURAt the close on Oct 30, 2026 · price × 348.0M shares outstanding
Swedish Orphan Biovitrum AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:SOBI · Home479.20 SEK-11.00 (-2.2%)374,273480.40488.60474.00490.20Close on Nov 2, 2026
OTC:BIOVF$45.72 USD0.00 (0.0%)—$45.72$45.72$45.72$45.72Close on Oct 27, 2026
OTC:SWOBY$20.28 USD-1.487 (-6.8%)621$20.28$20.28$20.28$21.77Close on Oct 19, 2026
Frankfurt:B6E€44.48 EUR+2.78 (+6.7%)—€44.48€44.48€44.48€41.70Close on Oct 30, 2026
Munich:B6E€42.82 EUR+2.14 (+5.3%)—€42.24€42.82€42.24€40.68Close on Oct 27, 2026
Ticker
Frankfurt:B6E
Asset type
Stock
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Replays

  • Swedish Orphan Biovitrum (Stockholm:SOBI) Q3 2026 Earnings Call

    Tue, Oct 27, 2026 · 10:00 AM ET

    Watch Transcript

  • Swedish Orphan Biovitrum (Stockholm:SOBI) Q2 2026 Earnings Call

    Thu, Jul 16, 2026 · 8:00 AM ET

    Watch Transcript

  • Swedish Orphan Biovitrum (Stockholm:SOBI) Q1 2026 Earnings Call

    Tue, Apr 28, 2026 · 6:30 AM ET

    Watch Transcript

Latest news

Börje Ekholm is proposed as new Chair of the Sobi Board of Directors

Oct 29, 2026

Swedish Orphan Biovitrum: Sobi receives positive CHMP opinion for TRYNGOLZA (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

Oct 16, 2026

Invitation: Sobi's Q3 2026 report

Oct 8, 2026

Change in number of shares and votes in Sobi

Sep 30, 2026

Sobi and Innate announce partnership is now effective following completion of closing conditions

Sep 16, 2026

Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome

Sep 9, 2026

Sobi has completed an issue of class C shares

Aug 31, 2026

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

Aug 10, 2026

Guido Oelkers to step down as CEO of Sobi in the beginning of 2027

Aug 3, 2026

Sobi Q2 2026 report: Significant growth with important pipeline progress

Jul 16, 2026

All Swedish Orphan Biovitrum AB news

Decks

Swedish Orphan Biovitrum AB on 6ix

News releases
46 in the last 12 months · 72 in all · newest Oct 29, 2026 · oldest 2025
Calls
15 calls with a replay · 15 with a transcript · latest Oct 27, 2026
Decks
87 decks · latest Oct 27, 2026

Where Swedish Orphan Biovitrum AB is listed

ListingExchangeCountryCurrency
Stockholm:SOBI · Home listingStockholmSwedenSEK
OTC:BIOVFOTCUnited StatesUSD
OTC:SWOBYOTCUnited StatesUSD
gettex:B6EgettexGermanyEUR
Milan:1SOBIMilanItalyEUR
LSIN:0MTDLSINUnited KingdomSEK
Aquis:SOBISAquisUnited KingdomSEK
BMV:SOBINBMVMexicoMXN
LS Exchange:A0LA5KLS ExchangeGermanyEUR
Lang & Schwarz:A0LA5KLang & SchwarzGermanyEUR
BIVA:SOBINBIVAMexicoMXN
Frankfurt:B6E · This pageFrankfurtGermanyEUR
Aquis:SOBISAquisUnited KingdomSEK
Turquoise:SOBISTurquoiseUnited KingdomSEK
Dusseldorf:B6EDusseldorfGermanyEUR
Hamburg:B6EHamburgGermanyEUR
Hanover:B6EHanoverGermanyEUR
Munich:B6EMunichGermanyEUR
Stuttgart:B6EStuttgartGermanyEUR
Tradegate:B6ETradegateGermanyEUR

Log in to ask 6ix AI your own questions about Swedish Orphan Biovitrum AB.